BIOMEDANA INDUSTRY INSIGHTS
Technology moves fast.
Biology asks for evidence.
Technology shifts in biologics, viewed through a founder's lens. BioMedAna perspectives on AI, bioprocess development and the path from research to manufacturing.
Perspectives for builders in biologics
AstraZeneca is moving AI deeper into biologics. Who owns the handoff?
AstraZeneca’s October 15, 2026 perspective puts AI inside biologics design. Our founder lens: the next bottleneck is carrying experimental context into development.
Industry event:
Six months to IND readiness? Read the decisions behind the timeline.
Lonza’s October 13, 2026 expansion of accelerated DNA-to-IND pathways raises a founder question: which development decisions must be ready earlier?
Industry event:
Lonza and Onava put expression data inside the AI loop. That is the signal.
The October 9, 2026 Lonza–Onava collaboration connects AI design with experimental expression data. Our take on what makes a biologics learning loop useful.
Industry event:
Hansa and Cradle: buying AI is the easy part. Changing the workflow is harder.
Hansa Biopharma and Cradle announced an AI protein-engineering partnership on October 1, 2026. Our founder perspective on adoption, evidence ownership and pilot design.
Industry event: